ClinicaliQ Trial Snapshot
- Phase 2/3 Study of KPL-387 in Recurrent Pericarditis — Recruiting • Phase II • Cardiology / Cardiovascular • NCT07010159.
- This study is being done to demonstrate whether KPL-387 is an effective and safe treatment for recurrent pericarditis.
- Sponsor: Kiniksa Pharmaceuticals International, plc.
Verify eligibility, endpoints and current status on the original source registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This study is being done to demonstrate whether KPL-387 is an effective and safe treatment for recurrent pericarditis.
Eligibility Snapshot
- Key Inclusion Criteria: * Phase 2 and 3: Has a diagnosis of recurrent pericarditis * Phase 2 and 3: Has signs and symptoms of recurrent pericarditis despite treatment with standard therapies * Phase 2 and 3: Weighs at least 40 kg * Phase 2: Taking NSAIDS and/or colchicine (in any combination) * Phase 3: Taking NSAIDs and/or colchicine and/or glucocorticoids (in any combination) Key
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.